Antisense oligonucleotide not checked
Novartis · NIO752
FollowEvery change as it happens, and a Monday email
Trials
3 active
4 in total · 2 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “A single intrathecal (cerebrospinal) injection of NIO752 of Dose A”In the company’s words, NCT05469360 on ClinicalTrials.gov
- Tested for
- Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS), Progressive Supranuclear Palsy, Corticobasal Degeneration, Frontotemporal Lobar Degeneration, Tauopathies, Alzheimer Disease, Mild Cognitive Impairment
- Main trialPhase 3
- “This Phase III study is intended to evaluate the efficacy and safety of NIO752 in participants with Progressive Supranuclear Palsy (PSP). Eligible participants will be randomized to receive either NIO752 or placebo followed by an open-label extension.”In the company’s words, NCT07498426 on ClinicalTrials.gov
- Other names
- NIO752
Other drugs for Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)
- ARO-MAPTArrowhead · Phase 1/2
- BepranemabUCB Biopharma SRL · Phase 1
Coming up2
- 26 Mar 2029Phase 2 trial completes · ClinicalTrials.gov
- 20 Jul 2029Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 20 Jul 2029 | A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy | |
| Phase 2Not yet recruiting | 26 Mar 2029 | A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of NIO752 in Primary Tauopathies | |
| Phase 1Active, not recruiting | 30 Jul 2026 | Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants | |
| Phase 1Completed | 17 Oct 2024 | Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026